Restructuring reward: A pilot study to enhance natural reward response in adults with cannabis use disorder.
Cannabis
Cannabis use disorder
Cortisol
Hedonic dysregulation
Imagery
Reward
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
received:
20
03
2023
revised:
31
05
2023
accepted:
08
06
2023
pmc-release:
01
08
2024
medline:
10
7
2023
pubmed:
18
6
2023
entrez:
17
6
2023
Statut:
ppublish
Résumé
Hedonic dysregulation is a core mechanism of addiction. There is a dearth of research on hedonic dysregulation in cannabis use disorder (CUD). The current study tested whether personalized scripted imagery may be an efficacious approach to remediate reward functioning in adults with CUD. Adults with CUD (n=10) and non-CUD controls (n=12) completed a single session personalized scripted imagery procedure. Non-drug (i.e. natural) reward and neutral scripts were transcribed and participants listened to the scripts in counterbalanced order. Primary outcomes included positive affect (PA), galvanic skin response (GSR), and cortisol and were assessed at four timepoints. Mixed effects models were used to compare between and within subject effects. Mixed effects models revealed a Condition (reward vs. neutral) X Group (CUD vs. control) interaction (p=0.01) on PA response, indicating blunted PA response to the neutral script relative to the reward script in CUD participants. Likewise, GSR response in CUD participants was decreased in response to the neutral script relative to the reward script (p=0.034; interaction n.s.). An interaction effect of Group X PA on cortisol response was found (p=.036) indicating that cortisol was positively correlated with PA in healthy control participants, but not CUD participants. Adults with CUD may demonstrate acute deficits in hedonic tone under neutral conditions relative to healthy controls. Personalized scripted imagery may be an efficacious tool to remediate hedonic dysregulation in CUD. Cortisol may play a role in healthy positive affect regulation warranting further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
Hedonic dysregulation is a core mechanism of addiction. There is a dearth of research on hedonic dysregulation in cannabis use disorder (CUD). The current study tested whether personalized scripted imagery may be an efficacious approach to remediate reward functioning in adults with CUD.
METHODS
METHODS
Adults with CUD (n=10) and non-CUD controls (n=12) completed a single session personalized scripted imagery procedure. Non-drug (i.e. natural) reward and neutral scripts were transcribed and participants listened to the scripts in counterbalanced order. Primary outcomes included positive affect (PA), galvanic skin response (GSR), and cortisol and were assessed at four timepoints. Mixed effects models were used to compare between and within subject effects.
RESULTS
RESULTS
Mixed effects models revealed a Condition (reward vs. neutral) X Group (CUD vs. control) interaction (p=0.01) on PA response, indicating blunted PA response to the neutral script relative to the reward script in CUD participants. Likewise, GSR response in CUD participants was decreased in response to the neutral script relative to the reward script (p=0.034; interaction n.s.). An interaction effect of Group X PA on cortisol response was found (p=.036) indicating that cortisol was positively correlated with PA in healthy control participants, but not CUD participants.
CONCLUSIONS
CONCLUSIONS
Adults with CUD may demonstrate acute deficits in hedonic tone under neutral conditions relative to healthy controls. Personalized scripted imagery may be an efficacious tool to remediate hedonic dysregulation in CUD. Cortisol may play a role in healthy positive affect regulation warranting further investigation.
Identifiants
pubmed: 37329729
pii: S0376-8716(23)01068-2
doi: 10.1016/j.drugalcdep.2023.110830
pmc: PMC10398752
mid: NIHMS1910397
pii:
doi:
Substances chimiques
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110830Subventions
Organisme : NIDA NIH HHS
ID : K23 DA045099
Pays : United States
Organisme : NIDA NIH HHS
ID : K24 DA038240
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors declare they have no conflict of interest.
Références
Psychol Med. 2007 Aug;37(8):1203-9
pubmed: 17274853
Sci Adv. 2019 Oct 16;5(10):eaax1569
pubmed: 31663023
Cochrane Database Syst Rev. 2019 Jan 28;1:CD008940
pubmed: 30687936
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
PLoS One. 2012;7(9):e44864
pubmed: 23049760
Psychol Med. 2023 Apr;53(5):2085-2094
pubmed: 37310337
Depress Anxiety. 2015 Apr;32(4):239-53
pubmed: 25703487
Pharmacotherapy. 2016 May;36(5):511-35
pubmed: 27027272
Addict Behav. 2011 Jan-Feb;36(1-2):140-3
pubmed: 20851531
Eur Neuropsychopharmacol. 2019 Mar;29(3):356-364
pubmed: 30658938
Adv Psychosom Med. 2011;30:22-60
pubmed: 21508625
Biol Psychol. 2015 Feb;105:124-9
pubmed: 25603284
Psychopharmacology (Berl). 2014 Apr;231(7):1397-407
pubmed: 24186078
Am J Psychiatry. 2005 Aug;162(8):1403-13
pubmed: 16055761
Am J Addict. 2017 Mar;26(2):136-144
pubmed: 28152236
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Addict Behav. 2012 Apr;37(4):373-8
pubmed: 22284583
Biol Psychiatry. 2009 Jul 15;66(2):100-1
pubmed: 19555787
Front Neuroendocrinol. 2021 Oct;63:100945
pubmed: 34461155
Psychother Psychosom. 2017;86(2):111-112
pubmed: 28183077
JAMA Netw Open. 2020 Apr 1;3(4):e202370
pubmed: 32271390
J Drug Issues. 2016 Jan;46(1):64-83
pubmed: 26877548
Front Psychiatry. 2023 Jan 19;14:1103739
pubmed: 36741122
JAMA Intern Med. 2022 Apr 01;182(4):407-417
pubmed: 35226053
Drug Alcohol Depend. 2023 Feb 1;243:109733
pubmed: 36565568
J Behav Med. 2015 Apr;38(2):327-36
pubmed: 25385024
Neuropsychopharmacology. 2001 Feb;24(2):97-129
pubmed: 11120394
Emotion. 2016 Jun;16(4):431-5
pubmed: 26950364
Evid Based Complement Alternat Med. 2017;2017:7018014
pubmed: 28373890
Neuropsychiatr Dis Treat. 2016 Aug 25;12:2149-64
pubmed: 27601909
J Psychopharmacol. 2008 Nov;22(8):836-42
pubmed: 18208907
Addict Behav. 2020 Oct;109:106479
pubmed: 32485547
Lancet Psychiatry. 2016 Aug;3(8):760-773
pubmed: 27475769
Addiction. 2008 May;103(5):787-99
pubmed: 18412757
Psychol Addict Behav. 2008 Dec;22(4):582-6
pubmed: 19071985
Neuropsychobiology. 2023;82(2):117-129
pubmed: 36812895
Hum Brain Mapp. 2016 Oct;37(10):3431-43
pubmed: 27168331